Difference between revisions of "Part:BBa K3822005"

(→‎1.Construction of the plasmids)
Line 14: Line 14:
 
==1.Construction of the plasmids==
 
==1.Construction of the plasmids==
 
The miRNA “ sponge” method was introduced by several years ago as a means to create continuous miRNA loss of function in cell lines and transgenic organisms. More effective are sponges containing bulged sites that are mispaired opposite miRNA positions 9-12 (Ebert et al. 2007, Gentner et al. 2009), presumably because they form a more stable interaction with the miRNA. pEGFP-miR196a-148a 2.0(Part K3822005) was designed based on the principle of effective sponges containing bulged sites (Fig. 1). We compare pEGFP-miR196a-148a 2.0 with pEGFP-miR196a-148a 1.0 (Part K3160007,designed by a 2019 iGEM team) on monitoring the expression of miRNAs in gastric cancer cells.
 
The miRNA “ sponge” method was introduced by several years ago as a means to create continuous miRNA loss of function in cell lines and transgenic organisms. More effective are sponges containing bulged sites that are mispaired opposite miRNA positions 9-12 (Ebert et al. 2007, Gentner et al. 2009), presumably because they form a more stable interaction with the miRNA. pEGFP-miR196a-148a 2.0(Part K3822005) was designed based on the principle of effective sponges containing bulged sites (Fig. 1). We compare pEGFP-miR196a-148a 2.0 with pEGFP-miR196a-148a 1.0 (Part K3160007,designed by a 2019 iGEM team) on monitoring the expression of miRNAs in gastric cancer cells.
−
[[File:T--YiYe-China--Improve1.png|400px|thumb|center| Fig 1. Pairing of a miRNA with a bulged sponge site shows mismatches opposite miRNA nucleotides.]]
+
[[File:T--YiYe-China--Improve1.png|400px|thumb|center| <b>Fig 1. Pairing of a miRNA with a bulged sponge site shows mismatches opposite miRNA nucleotides.</b>]]
−
 
+
The plasmids of pEGFP-miR-196a-148a 2.0 was synthesized by Nanjing Qingke Biotechnology Corporation. The electrophoresis of the plasmids was showed in Fig 2.
 +
[[File:T--YiYe-China--Improve2.png|400px|thumb|center| <b>Fig 2. Electrophoresis of pEGFP-miR-196a-148a 2.0.</b>]]
 +
==2. The effect of pEGFP-miR-196a-148a 1.0 and pEGFP-miR-196a-148a 2.0 in gastric cancer cells==
 +
To detect the validity of pEGFP-miR-196a-148a 1.0 and pEGFP-miR196a-148a 2.0 in cells, pEGFP–C1 (as negative controls), pEGFP-miR-196a-148a 1.0 or pEGFP-miR-196a-148a 2.0 (0.5 ug plasmids for each well) was transfected into human gastric epithelial cells (GES-1 cells) in 24-well plate, respectively. After transfection, cells were examined under fluorescence microscopy (Fig 3A-C). The fluorescence of GFP was decreased in GES-1 cells transfected with pEGFP-miR-196a-148a 1.0 and pEGFP-miR-196a-148a 2.0 compared with controls (Fig 3 A-C). Because pEGFP-miR-196a-148a 2.0 contains more effective binding sites than pEGFP-miR-196a-148a 1.0, the fluorescence of GFP was further decreased in GES-1 cells transfected with pEGFP-miR-196a-148a 2.0 compared with that in cells transfected with pEGFP-miR-196a-148a 1.0 (Fig. 3 and Table 1). In addition, we also measured the value of GFP fluorescence by plate reader (SpectraMax i3) (Fig. 3-4 and Table. 1). The similar results were also observed in SGC-7901 cells (gastric cancer cell line) (Fig. 3-4, and Table 1). Compared with pEGFP-miR-196a-148a 1.0, pEGFP-miR-196a-148a 2.0 is more effective to be inhibited by the endogenous miRNAs (Fig. 3 and Table. 1).
 +
[[File:T--YiYe-China--Improve3.png|600px|thumb|center|<b> Fig 3. The images of different gastric cells transfected with different plasmids. </b>(A). pEGFP–C1 (control) was transfected in GES-1 cells. (B). pEGFP-miR-196a-148a 1.0 was transfected in GES-1 cells. (C). pEGFP-miR-196a-148a 2.0 was transfected in GES-1 cells. (D). pEGFP–C1 (control) was transfected in SGC-7901 cells. (E). pEGFP-miR-196a-148a sensor 1.0 was transfected in SGC-7901 cells. (F). pEGFP-miR-196a-148a sensor 2.0 was transfected in SGC-7901 cells.]]
 
<!-- Uncomment this to enable Functional Parameter display  
 
<!-- Uncomment this to enable Functional Parameter display  
 
===Functional Parameters===
 
===Functional Parameters===
 
<partinfo>BBa_K3822005 parameters</partinfo>
 
<partinfo>BBa_K3822005 parameters</partinfo>
 
<!-- -->
 
<!-- -->

Revision as of 02:14, 15 October 2021


miR196a-148a 2.0

miR196a-148a 2.0 is an improvement of Part BBa_K3160007. which could monitor the expression of miRNAs in gastric cancer cells

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]

Result

1.Construction of the plasmids

The miRNA “ sponge” method was introduced by several years ago as a means to create continuous miRNA loss of function in cell lines and transgenic organisms. More effective are sponges containing bulged sites that are mispaired opposite miRNA positions 9-12 (Ebert et al. 2007, Gentner et al. 2009), presumably because they form a more stable interaction with the miRNA. pEGFP-miR196a-148a 2.0(Part K3822005) was designed based on the principle of effective sponges containing bulged sites (Fig. 1). We compare pEGFP-miR196a-148a 2.0 with pEGFP-miR196a-148a 1.0 (Part K3160007,designed by a 2019 iGEM team) on monitoring the expression of miRNAs in gastric cancer cells.

Fig 1. Pairing of a miRNA with a bulged sponge site shows mismatches opposite miRNA nucleotides.

The plasmids of pEGFP-miR-196a-148a 2.0 was synthesized by Nanjing Qingke Biotechnology Corporation. The electrophoresis of the plasmids was showed in Fig 2.

Fig 2. Electrophoresis of pEGFP-miR-196a-148a 2.0.

2. The effect of pEGFP-miR-196a-148a 1.0 and pEGFP-miR-196a-148a 2.0 in gastric cancer cells

To detect the validity of pEGFP-miR-196a-148a 1.0 and pEGFP-miR196a-148a 2.0 in cells, pEGFP–C1 (as negative controls), pEGFP-miR-196a-148a 1.0 or pEGFP-miR-196a-148a 2.0 (0.5 ug plasmids for each well) was transfected into human gastric epithelial cells (GES-1 cells) in 24-well plate, respectively. After transfection, cells were examined under fluorescence microscopy (Fig 3A-C). The fluorescence of GFP was decreased in GES-1 cells transfected with pEGFP-miR-196a-148a 1.0 and pEGFP-miR-196a-148a 2.0 compared with controls (Fig 3 A-C). Because pEGFP-miR-196a-148a 2.0 contains more effective binding sites than pEGFP-miR-196a-148a 1.0, the fluorescence of GFP was further decreased in GES-1 cells transfected with pEGFP-miR-196a-148a 2.0 compared with that in cells transfected with pEGFP-miR-196a-148a 1.0 (Fig. 3 and Table 1). In addition, we also measured the value of GFP fluorescence by plate reader (SpectraMax i3) (Fig. 3-4 and Table. 1). The similar results were also observed in SGC-7901 cells (gastric cancer cell line) (Fig. 3-4, and Table 1). Compared with pEGFP-miR-196a-148a 1.0, pEGFP-miR-196a-148a 2.0 is more effective to be inhibited by the endogenous miRNAs (Fig. 3 and Table. 1).

Fig 3. The images of different gastric cells transfected with different plasmids. (A). pEGFP–C1 (control) was transfected in GES-1 cells. (B). pEGFP-miR-196a-148a 1.0 was transfected in GES-1 cells. (C). pEGFP-miR-196a-148a 2.0 was transfected in GES-1 cells. (D). pEGFP–C1 (control) was transfected in SGC-7901 cells. (E). pEGFP-miR-196a-148a sensor 1.0 was transfected in SGC-7901 cells. (F). pEGFP-miR-196a-148a sensor 2.0 was transfected in SGC-7901 cells.